[
{
	"page":"ENAS5283_1.0.0.0",
	"text":"1.0.0.0 Authors and Publication  GUIDELINES COMMITTEE Chair: George Pentheroudakis; Co-‍Chair: Cristiana Sessa; Steering Committee Members: Dirk Arnold, Christian Buske, Fatima Cardoso, Paolo Casali, Andrés Cervantes, Elisabeth de Vries, Alan Horwich, Solange Peters, Rolf Stahel; Subject Editors: Jean-‍Yves Blay, Nicoletta Colombo, Karin Jordan, Ulrich Keilholz, Marco Ladetto, Lisa Licitra, Matthias Preusser, Carla Ripamonti, Elzbieta Senkus-‍‍Konefka; Deputy Subject Editors: Alfredo Berruti, Silke Gillessen, Mats Jerkeman, Jean-Pascal Machiels, Erika Martinelli, Ulrich Mey, Olivier Michielin, Martin Reck; Staff: Keith McGregor, Claire Bramley, Jennifer Lamarre, Sarah Escuin, Jean-Yves Douillard, Svetlana Jezdic. ESMO CLINICAL PRACTICE GUIDELINES Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-‍up Lordick F, Mariette C, Haustermans K, Obermannová R and Arnold D, on behalf of the ESMO Guidelines Committee Ann Oncol 2016; 27 (Suppl 5): v50-7 https:/‍/‍annonc.oxfordjournals.org/‍content/27/‍suppl_5/v50.full.pdf+html Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-‍up Smyth EC, Verheij M, Allum W, Cunningham D, Cervantes A and Arnold D, on behalf of the ESMO Guidelines Committee Ann Oncol 2016; 27 (Suppl 5): v38–49 https:/‍/‍annonc.oxfordjournals.org/‍content/27/‍suppl_5/v38.full.pdf+html Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-‍up Valle JW, Borbath I, Khan SA, Huguet F, Gruenberger T and Arnold D, on behalf of the ESMO Guidelines Committee Ann Oncol 2016; 27 (Suppl 5): v28-37 https:/‍/‍annonc.oxfordjournals.org/‍content/27/‍suppl_5/v28.full.pdf+html Hepatocellular carcinoma: ESMO-‍ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-‍up Verslype C, Rosmorduc O and Rougier P, on behalf of the ESMO Guidelines Working Group Ann Oncol 2012:23(Suppl 7)vii41-48 https:/‍/‍annonc.oxfordjournals.org/‍content/‍23/‍suppl_7/vii41.full.pdf+html Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-‍up Ducreux M, Sa Cuhna A, Caramella C, Hollebecque A, Burtin P, Goéré D, Seufferlein T, Haustermans K, Van Laethem JL, Conroy T and Arnold D, on behalf of the ESMO Guidelines Committee Ann Oncol 2015; 26(Suppl 5):v56-68 https:/‍/‍annonc.oxfordjournals.org/‍content/‍26/‍suppl_5/v56.full.pdf+html ESMO POCKET GUIDELINES PROVIDE YOU WITH A CONCISE SUMMARY OF THE FUNDAMENTAL RECOMMENDATIONS MADE IN THE PARENT GUIDELINES IN AN EASILY ACCESSIBLE FORMAT. This quick reference booklet provides you with the most important content of the full ESMO Clinical Practice Guidelines (CPG) on upper gastrointestinal (GI) tumours (oesophageal cancer, gastric cancer, biliary cancer, hepatocellular carcinoma and pancreatic adenocarcinoma). Key content includes diagnostic criteria, staging of disease, treatment plans and follow-‍up. The ESMO CPG on upper GI tumours are intended to provide you with a set of recommendations for the best standards of care for upper GI tumours, using evidence-‍based medicine. Implementation of ESMO CPG facilitates knowledge uptake and helps you to deliver an appropriate quality of focused care to your patients. The approval and licensed indication of drugs mentioned in this pocket guideline may vary in different countries. Please consult your local prescribing information. This booklet can be used as a quick reference guide to access key content on evidence-‍based management of upper GI tumours. Please visit http://www.esmo.org or http:/‍/‍oncologypro.esmo.org to view the full guidelines."
},
{
	"page":"ENAS5283_2.0.0.0",
	"text":"2.0.0.0 DIAGNOSIS AND PATHOLOGY Clinical symptoms are unspecific, but commonly include weight loss, dysphagia, dyspepsia, vomiting, early satiety and/‍or iron deficiency anaemia Diagnosis of gastric cancer should be made from a gastroscopic or surgical biopsy reviewed by an experienced pathologist and histology should be reported according to the World Health Organization (WHO) criteria Most (90%) gastric cancers are adenocarcinomas (ACs), which are subdivided histologically into diffuse (undifferentiated) and intestinal (well-‍differentiated) types (Lauren classification) Four molecularly defined subtypes across genomic, transcriptomic and proteomic levels do not yet have any impact on treatment Referral to a geneticist for assessment is recommended, based on international clinical guidelines, where a familial cancer syndrome, such as hereditary diffuse gastric cancer (HDGC), is suspected Gastrointestinal stromal tumours (GIST), lymphomas and neuroendocrine tumours are not covered by these guidelines"
},
{
	"page":"ENAS5283_3.1.0.0",
	"text":"3.0.0.0 STAGING AND RISK ASSESSMENT 3.1.0.0 Overview Initial staging and risk assessment should include physical examination, blood count and differential, liver and renal function tests, endoscopy and contrast enhanced computed tomography (CT) scanning of the thorax, abdomen ± pelvis, as shown in the table below DIAGNOSTIC AND STAGING INVESTIGATIONS IN GASTRIC CANCER PROCEDURE PURPOSE Endoscopy and biopsy Obtain tissue for diagnosis, histological classification and molecular biomarkers e.g. HER2 status CT thorax + abdomen ± pelvis Staging of tumour – to detect local/‍distant lymphadenopathy and metastatic disease or ascites EUS Accurate assessment of T and N stage in potentially operable tumours Determine proximal and distal extent of tumour Laparoscopy ± washings Exclude occult metastatic disease involving peritoneum/‍diaphragm PET, if available May improve detection of occult metastatic disease in some cases CT, computed tomography; EUS, endoscopic ultrasound; HER2, human epidermal growth factor receptor 2; N, node; T, tumour; PET, positron emission tomography There is no global consensus on specific diagnostic criteria Malignant lymph nodes detected on CT commonly have a short axis diameter 6–8 mm in perigastric lymph nodes, round shape, central necrosis and heterogeneous or high enhancement Endoscopic ultrasound (EUS) is helpful in determining the proximal and distal extent of the tumour and provides further T and N stage assessment; however, it is less useful in antral tumours EUS is more accurate than CT for the diagnosis of malignant lymph nodes, malignancy patterns including hypo-‍echogenicity, round shape, smooth, distinct margin and size >1 cm Positron emission tomography (PET)-CT imaging may improve staging by detecting involved lymph nodes or metastatic disease PET is not informative in patients with mucinous or diffuse tumours Laparoscopy ± peritoneal washings for malignant cells is recommended in all potentially resectable stage IB–III gastric cancers, to exclude radiologically occult metastatic disease; the benefit may be greater for patients with T3/T4 disease Staging should be according to the latest edition of the American Joint Committee on Cancer (AJCC)/‍Union for International Cancer Control (UICC) guidelines and staging manual, as shown in the tables here"
},
{
	"page":"ENAS5283_3.2.0.0",
	"text":"3.2.0.0 TNM staging STAGING OF GASTRIC CANCER ACCORDING TO THE AJCC TNM STAGING SYSTEM, 7TH EDITION PRIMARY TUMOUR (T) TX Primary tumour cannot be assessed T0 No evidence of primary tumour Tis Carcinoma in situ: intraepithelial tumour without invasion of the lamina propria T1a Tumour invades lamina propria or muscularis mucosae T1b Tumour invades submucosa T2 Tumour invades muscularis propria T3 Tumour penetrates subserosal connective tissue without invasion of visceral peritoneum or adjacent structures* T4 Tumour invades serosa (visceral peritoneum) or adjacent structures† T4a Tumour invades serosa (visceral peritoneum) T4b Tumour invades adjacent structures† REGIONAL LYMPH NODES (N) NX Regional lymph node(s) cannot be assessed N0 No regional lymph node metastasis N1 Metastasis in 1–2 regional lymph nodes N2 Metastasis in 3–6 regional lymph nodes N3 Metastasis in 7 or more regional lymph nodes N3a Metastasis in 7–15 regional lymph nodes N3b Metastasis in 16 or more regional lymph nodes DISTANT METASTASIS (M) M0 No distant metastasis M1 Distant metastasis or positive peritoneal cytology AJCC, American Joint Committee on Cancer; TNM, tumour node metastasis *T3 tumours also include those extending into the gastrocolic or gastrohepatic ligaments, or into the greater or lesser omentum, without perforation of the visceral peritoneum covering these structures †Adjacent structures include the spleen, transverse colon, liver, diaphragm, pancreas, abdominal wall, adrenal gland, kidney, small intestine and retro-‍peritoneum Edge SB, Byrd DR, Compton CC, eds. AJCC Cancer Staging Handbook, 7th ed. New York, NY.: Springer, 2010. Used with the permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original source for this material is the AJCC Cancer Staging Handbook, Seventh Edition (2010) published by Springer Science and Business Media LLC, www.springer.com"
},
{
	"page":"ENAS5283_3.3.0.0",
	"text":"3.3.0.0 Anatomic stage/‍ prognostic groups ANATOMIC STAGE / PROGNOSTIC GROUPS ACCORDING TO THE AJCC TNM STAGING SYSTEM, 7TH EDITION STAGE GROUPING T-‍STAGE N-‍STAGE M-‍STAGE Stage 0 Tis N0 M0 Stage IA T1 N0 M0 Stage IB   T2 N0 M0 T1 N1 M0 Stage IIA     T3 N0 M0 T2 N1 M0 T1 N2 M0 Stage IIB       T4a N0 M0 T3 N1 M0 T2 N2 M0 T1 N3 M0 Stage IIIA     T4a N1 M0 T3 N2 M0 T2 N3 M0 Stage IIIB     T4b N0-1 M0 T4a N2 M0 T3a N3 M0 Stage IIIC   T4b N2-3 M0 T4a N3 M0 Stage IV Any T Any N M1 TNM, Tumour Node Metastasis Edge SB, Byrd DR, Compton CC, eds. AJCC Cancer Staging Handbook, 7th ed. New York, NY.: Springer, 2010. Used with the permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original source for this material is the AJCC Cancer Staging Handbook, Seventh Edition (2010) published by Springer Science and Business Media LLC, www.springer.com."
},
{
	"page":"ENAS5283_4.1.0.0",
	"text":"4.0.0.0 Treatment 4.1.0.0 Treatment Multidisciplinary treatment planning before any treatment is mandatory. The core team membership includes surgeons, medical and radiation oncologists, radiologists and pathologists, with other members as available A treatment algorithm is shown in the figure here"
},
{
	"page":"ENAS5283_4.3.1.0",
	"text":"4.3.0.0 Mgmt. of local/‍ locoregional disease 4.3.1.0 Surgery Surgical resection, specifically at early stages, is potentially curative. However, the high incidence of post-‍resection relapse means that combined modality therapies are standard for ≥ stage IB disease Endoscopic resection is appropriate for selected very early gastric cancers (T1a) if they are clearly confined to the mucosa, well-‍differentiated, ≤2 cm and non-ulcerated and the associated lymph node metastatic risk is extremely low The European Society of Gastrointestinal Endoscopy (ESGE) guidelines recommend endoscopic submucosal dissection (ESD) for most superficial neoplastic lesions, although endoscopic mucosal resection (EMR) is acceptable for lesions smaller than 10–15 mm with a low probability of advanced histology T1 tumours not meeting endoscopic resection criteria require surgery Lymph node dissection for T1 tumours may be confined to perigastric lymph nodes and include local N2 nodes; sentinel lymph node mapping may further modify these approaches For stage IB–III gastric cancer, radical gastrectomy is indicated and perioperative therapy is recommended for these patients Sub-‍total gastrectomy may be performed if a macroscopic proximal margin of 5 cm (8 cm for diffuse cancers) can be achieved between the tumour and the gastroesophageal junction (GEJ); otherwise, a total gastrectomy is indicated The UICC/‍AJCC TNM (7th edition) classification recommends excision of a minimum of 15 lymph nodes for reliable staging Observational and randomised trial data from Asian countries demonstrate that D2 dissection (removal of perigastric lymph nodes plus those along the left gastric, common hepatic and splenic arteries and coeliac axis) leads to superior outcomes compared with D1 resection (removal of the perigastric lymph nodes) In Western countries, medically fit patients should undergo D2 resections in specialised, high-‍volume centres with appropriate surgical expertise and postoperative care Laparoscopic surgery has the potential benefit of decreased postoperative morbidity and reduced recovery time and is becoming one of the recommended options for patients with early gastric cancer Whether it can achieve the same results as open surgery in gastric cancers requiring D2 lymphadenectomy requires confirmation"
},
{
	"page":"ENAS5283_4.3.2.0",
	"text":"4.3.2.0 Perioperative chemotherapy Perioperative platinum/‍fluoropyrimidine combination chemotherapy is recommended for patients with ≥ stage IB resectable gastric cancer, as it has shown prolonged survival in resectable stage II and III gastric cancers Perioperative (pre- and postoperative) chemotherapy with FLOT (5-fluorouracil [5-FU] leucovorin/oxaliplatin/docetaxel) has improved overall survival (OS) in a phase III trial when compared to ECF (epirubicin/cisplatin/5-FU)/ECX (epirubicin/cisplatin/capecitabine), as well as rates of pathological complete remission (pCR), and should be regarded as standard of care for patients with ≥ Stage IB resectable gastric and gastroesophageal junction cancers There is no evidence to support the use of perioperative trastuzumab therapy or any other biologically targeted drug, including anti-‍angiogenic compounds"
},
{
	"page":"ENAS5283_4.3.3.1",
	"text":"As adjuvant chemotherapy is less well-tolerated than neoadjuvant chemotherapy, a perioperative approach is preferred if possible 4.3.3.0 Adjuvant treatment 4.3.3.1 Overview For patients with ≥ stage IB gastric cancer who have undergone surgery without administration of preoperative chemotherapy (e.g. due to understaging before initial decision for upfront surgery), postoperative chemoradiotherapy (CRT) or adjuvant chemotherapy is recommended"
},
{
	"page":"ENAS5283_4.3.3.2",
	"text":"4.3.3.2 Chemoradiotherapy Adjuvant 5-‍FU/leucovorin therapy plus conventionally fractionated radiotherapy (RT) improves long-‍term survival compared with surgery alone and is considered standard therapy in the United States but not in Europe Around 50% of the patients in the study involved underwent less than D1 resection and, therefore, postoperative CRT should not be seen as the best proven modality in a standard setting (with D2 dissection) Other randomised and non-‍randomised data suggest potential benefits from postoperative CRT even after optimal D2 dissection The use of CRT after microscopically incomplete R1 resection improves survival and local recurrence rates RT, within a concomitant regimen of fluoropyrimidine-‍based CRT, should be administered to a total dose of 45 Gy in 25 fractions of 1.8 Gy, 5 fractions/week by intensity-‍modulated RT techniques The clinical target volume encompasses the gastric bed (with stomach remnant when present), anastomoses and draining regional lymph nodes"
},
{
	"page":"ENAS5283_4.3.3.3",
	"text":"4.3.3.3 Chemotherapy There is an overall survival (OS) benefit associated with adjuvant chemotherapy with S-1 following D2 resection in Asian patients – with similar findings for capecitabine-‍oxaliplatin doublet in a comparable population The benefit of 5-‍FU-‍based adjuvant chemotherapy compared with surgery alone, which was documented in numerous meta-‍analyses, has been confirmed Sequential and/‍or intensified regimens have no benefit compared with single agent treatment"
},
{
	"page":"ENAS5283_4.3.3.4",
	"text":"4.3.3.4 Following preop. chemotherapy The preoperatively chosen regimen should be completed after resection for patients who are fit for treatment, independent from patho-‍histological findings and considerations The addition of postoperative RT has been shown to not improve survival in patients receiving chemotherapy before and after curative-intent surgery"
},
{
	"page":"ENAS5283_2018031939",
	"text":"4.4.0.0 Mgmt. of advanced/ metastatic disease Patients with inoperable locally advanced and/‍or metastatic (stage IV) disease should be considered for systemic treatment (chemotherapy), which has shown improved survival and quality of life (QoL) compared with best supportive care (BSC) alone Comorbidities, organ function and performance status (PS) must be taken into consideration In general, primary tumour resection is not recommended in the palliative setting, but may be an option following a good response to systemic therapy in asymptomatic patients with initially unresectable locally advanced disease Interval imaging of chest, abdomen and pelvis is recommended for systemic treatment response assessment, mostly with CT – although alternative imaging techniques may be used to monitor known disease sites (e.g. magnetic resonance imaging [MRI] for bone lesions) Platinum/fluoropyrimidine doublet alone or in combination with further compounds (triplet combinations; with epirubicin or with taxanes) are recommended for fit patients with advanced gastric cancer All combinations like the ECF, ECX, EOF (epirubicin/‍oxaliplatin/‍5-FU) and EOX regimens in general provide similar efficacy Compared with ECF, EOX provides good survival without the need for an indwelling catheter Within doublet and triplet regimens, capecitabine improves OS compared with infused 5-FU Triplets containing taxanes are another first-‍line chemotherapy option The addition of docetaxel to cisplatin/‍5-FU (DCF) in a 3-‍weekly regimen improves OS, but increases toxicity, including febrile neutropaenia A substantially modified 2-‍weekly DCF regimen is tolerable and effective The FLOT regimen is associated with encouraging results Infusional 5-‍FU/‍leucovorin/‍irinotecan (FOLFIRI) may be considered as an alternative to platinum-‍based therapy for selected patients Surgery for stage IV gastric cancer is to be discussed (see Metastasectomy section)"
},
{
	"page":"ENAS5283_4.5.0.0",
	"text":"4.5.0.0 Elderly patients with gastric cancer There are few randomised data in elderly patients Phase II trials have shown comparable survival with capecitabine/‍oxaliplatin, 5-‍FU/leucovorin/oxaliplatin (FOLFOX), single-‍agent capecitabine and S-1 (in Asian patients) Response rates or OS following chemotherapy are similar in patients ≥ 70 years and younger patients The triple agent regimen FLOT is associated with a trend towards improved PFS, compared with 5-‍FU/leucovorin/‍oxaliplatin (FLO), but also increased toxicity Generally, chemotherapy treatment decisions should consider the functional age of the patient, including comorbidities and PS, and geriatric assessment may also be helpful"
},
{
	"page":"ENAS5283_4.6.0.0",
	"text":"4.6.0.0 Second-‍ and further-‍line treatment Second-‍line treatment provides OS and QoL benefits compared with BSC in patients with adequate PS Chemotherapy with a taxane (docetaxel, paclitaxel), or irinotecan, or the vascular endothelial growth factor receptor 2 inhibitor ramucirumab (either alone or in combination with paclitaxel) have proven efficacy in refractory patients with gastric cancer Ramucirumab has shown improved OS in two phase III trials: Compared with placebo when administered as a single agent and when added to paclitaxel compared with paclitaxel alone Paclitaxel and irinotecan seem to have similar efficacy In patients with disease progression > 3 months following first-‍line chemotherapy, re-‍challenge with the same drug combination may be considered as an additional treatment option In patients with symptomatic, locally-‍advanced or recurrent disease, hypofractionated RT is an effective and well-‍tolerated treatment modality that may palliate bleeding, obstructive symptoms or pain"
},
{
	"page":"ENAS5283_5.0.0.0",
	"text":"5.0.0.0 Personalised medicine and targeted therapy The Cancer Genome Atlas describes four subtypes of gastric cancer: Epstein Barr Virus, microsatellite instability (MSI) high, genomically stable and chromosomal instability (CIN), the latter of which is enriched for copy number changes in key receptor tyrosine kinase oncogenes such as HER2, epidermal growth factor receptor (EGFR), fibroblast growth factor receptor 2 (FGFR2) and MET. However, this is currently without relevance for therapeutic decision Trastuzumab in combination with capecitabine or 5-FU and cisplatin is recommended for the treatment of patients with HER2-‍positive advanced gastric cancer, as shown in the table below, which accounts for 10–15% of cases PERSONALISED MEDICINE SYNOPSIS TABLE FOR LOWER OESOPHAGEAL AND GASTRIC CANCER BIOMARKER METHOD USE LOE, GOR HER2 IHC for HER2 protein expression or ISH for HER2 gene amplification Used to select patients with metastatic disease for treatment with a trastuzumab-‍containing regimen I, A GOR, grade of recommendation; HER2, human epidermal growth factor receptor 2; IHC, immunohistochemistry; ISH, in situ hybridisation; LOE, level of evidence Bevacizumab, anti-‍EGFR and anti-‍MET/hepatocyte growth factor (HGF) therapies do not provide (substantial) survival benefits Immunotherapies, such as the programmed death 1 (PD-1) inhibitors pembrolizumab and nivolumab, may provide durable benefit for some patients with advanced gastric cancer. Results from controlled trials are awaited The interaction between immunotherapy and other known gastric cancer biomarkers, such as MSI, requires further investigation"
},
{
	"page":"ENAS5283_2018031941",
	"text":"In general, resection of metastases does not provide benefits, although prolonged survival has been demonstrated for selected patients undergoing liver and lung metastasectomy and surgical removal of Krukenberg tumours Gastrectomy in patients with limited metastatic disease does not improve survival Currently, gastrectomy and metastasectomy should be considered experimental for patients with gastric cancer"
},
{
	"page":"ENAS5283_2018031942",
	"text":"Adjuvant hyperthermic intraperitoneal chemotherapy (HIPEC) provides survival benefits in high-‍risk, curatively resected gastric cancer patients and those with advanced peritoneal metastases There are no randomised data for non-‍Asian patients, although promising results have been demonstrated for surgery plus HIPEC in a large French series Currently, this approach cannot be recommended outside the context of clinical research  "
},
{
	"page":"ENAS5283_2018031940",
	"text":"6.0.0.0 Specific situations Gastric AC associated with signet ring cells is associated with a poor prognosis and may be less sensitive to chemotherapy and CRT Currently, standard chemotherapy or surgical approaches should not be used differently for these patients"
},
{
	"page":"ENAS5283_7.0.0.0",
	"text":"FOLLOW-UP, LONG-TERM IMPLICATIONS AND SURVIVORSHIP 7.0.0.0 F-up, long term implic. & survivorship The symptoms associated with operable gastric cancer treatment can adversely affect health-‍related QoL Regular follow-‍up may allow investigation and treatment of symptoms, psychological support and early detection of recurrence, although there is no evidence that it improves survival outcomes Follow-‍up should be tailored to the individual patient and the stage of the disease Dietary support for vitamin and mineral deficiencies is recommended for patients on either a radical or a palliative pathway Patient-‍led self-‍referral and services led by clinical nurse specialists are among the new strategies being investigated In the advanced disease setting, identification of patients for second-‍line chemotherapy and clinical trials requires regular follow-‍up to detect symptoms of disease progression prior to significant clinical deterioration If relapse/disease progression is suspected, a clinical history, physical examination and directed blood tests should be carried out, with radiological investigations in patients who are candidates for further chemotherapy or RT Given the poor outcomes, even in operable disease, the concept of survivorship is only now beginning to evolve and there is little information on the long-‍term implications, late effects of therapy and psychosocial implications of treatment"
},
{
	"page":"ENAS5283_8.1.0.0",
	"text":"8.0.0.0 Summary of recommendations 8.1.0.0 DIAGNOSIS AND PATHOLOGY Clinical symptoms are unspecific, but commonly include weight loss, dysphagia, dyspepsia, vomiting, early satiety and/‍or iron deficiency anaemiaDiagnosis should be made from a gastroscopic or surgical biopsy reviewed by an experienced pathologist and histology should be reported according to the WHO criteria [IV, C]Referral to a geneticist for assessment is recommended, based on international clinical guidelines, where a familial cancer syndrome, such as HDGC, is suspected [V, B]"
},
{
	"page":"ENAS5283_8.2.0.0",
	"text":"8.2.0.0 STAGING AND RISK ASSESSMENT Initial staging and risk assessment should include physical examination, blood count and differential, liver and renal function tests, endoscopy and contrast enhanced CT scanning of the thorax, abdomen &pm; pelvis [V, A]There is no global consensus on specific diagnostic criteriaEUS is helpful in determining the proximal and distal extent of the tumour and provides further T and N stage assessment; however, it is less useful in antral tumours [III, B] EUS is more accurate than CT for the diagnosis of malignant lymph nodes PET-‍CT imaging may improve staging by detecting involved lymph nodes or metastatic disease PET is not informative in patients with mucinous or diffuse tumours [III, B] Laparoscopy &pm; peritoneal washings for malignant cells is recommended in all potentially resectable stage IB–III gastric cancers, to exclude radiologically occult metastatic disease; the benefit may be greater for patients with T3/T4 disease [III, B] Staging should be according to the latest edition of the AJCC/‍UICC guidelines and staging manual"
},
{
	"page":"ENAS5283_2018032044",
	"text":"Multidisciplinary treatment planning before any treatment is mandatory [IV, C]"
},
{
	"page":"ENAS5283_8.3.1.1",
	"text":"8.3.0.0 Treatment 8.3.1.0 Mgmt. of local/‍ locoregional disease 8.3.1.1 Surgery Surgical resection, specifically at early stages, is potentially curative. However, combined modality therapies are standard for ≥ stage IB disease Endoscopic resection is appropriate for selected very early gastric cancers (T1a) if they are clearly confined to the mucosa, well-‍differentiated, ≤ 2 cm and non-‍ulcerated [III, B] ESGE guidelines recommend ESD for most superficial neoplastic lesions [IV, B], although EMR is acceptable for lesions smaller than 10–15 mm with a low probability of advanced histology T1 tumours not meeting endoscopic resection criteria require surgery Lymph node dissection for T1 tumours may be confined to perigastric lymph nodes and include local N2 nodes For stage IB–III gastric cancer, radical gastrectomy is indicated and perioperative therapy is recommended for these patients [I, A] Sub-‍total gastrectomy may be performed if a macroscopic proximal margin of 5 cm (8 cm for diffuse cancers) can be achieved between the tumour and the GEJ; otherwise, a total gastrectomy is indicated [III, A] Excision of a minimum of 15 lymph nodes is required for reliable staging Observational and randomised trial data from Asian countries demonstrate that D2 dissection leads to superior outcomes compared with D1 resection [II, B] Consensus opinion is that, in Western countries, medically fit patients should undergo D2 resections in specialised, high-‍volume centres with appropriate surgical expertise and postoperative care [I, B] Laparoscopic surgery is becoming a recommended option for early gastric cancer"
},
{
	"page":"ENAS5283_8.3.1.2",
	"text":"8.3.1.2 Perioperative chemotherapy Perioperative platinum/‍fluoropyrimidine combination chemotherapy is recommended for patients with ≥ stage IB resectable gastric cancer [I, A] Perioperative FLOT has improved OS and should be regarded as standard of care for patients with ≥ Stage IB resectable gastric and gastroesophageal junction cancers [I, A] There is no evidence to support the use of perioperative trastuzumab therapy or any other biologically targeted drug, including anti-angiogenic compounds"
},
{
	"page":"ENAS5283_8.3.1.3",
	"text":"8.3.1.3 Adjuvant treatment For patients with ≥ stage IB gastric cancer who have undergone surgery without administration of preoperative chemotherapy, postoperative CRT or adjuvant chemotherapy is recommended [I, A] Chemoradiotherapy Adjuvant 5-‍FU/leucovorin therapy plus conventionally fractionated RT improves long-‍term survival compared with surgery alone [I, A] and is considered standard therapy in the United States but not in Europe Other randomised and non-‍randomised data suggest potential benefits from postoperative CRT even after optimal D2 dissection [I, B] The use of CRT after microscopically incomplete R1 resection improves survival and local recurrence rates [IV, B] RT, within a concomitant regimen of fluoropyrimidine-‍based CRT, should be administered to a total dose of 45 Gy in 25 fractions of 1.8 Gy, 5 fractions/week by intensity-‍modulated RT techniques [IV, A] The clinical target volume encompasses the gastric bed (with stomach remnant when present), anastomoses and draining regional lymph nodes [I, B] Chemotherapy OS benefit has been demonstrated for patients treated with adjuvant chemotherapy [I, A] The benefit of 5-‍FU-‍based adjuvant chemotherapy compared with surgery alone has been confirmed [I, A] Sequential and/‍or intensified regimens have no benefit compared with single agent treatment A perioperative approach is preferred if possible Adjuvant treatment following preoperative chemotherapy The preoperatively chosen regimen should be complete after resection for patients who are fit for treatment, independent from patho-‍histological findings and considerations Addition of postoperative RT has been shown to not improve survival in patients receiving chemotherapy before and after curative-intent surgery"
},
{
	"page":"ENAS5283_2018031943",
	"text":"8.3.2.0 Mgmt. of advanced/ metastatic disease Patients with inoperable locally advanced and/‍or metastatic (stage IV) disease should be considered for systemic treatment (chemotherapy), which has shown improved survival and QoL compared with BSC alone [I, A] Comorbidities, organ function and PS must be taken into consideration [II, B] In general, primary tumour resection is not recommended in the palliative setting, but may be an option following a good response to systemic therapy in patients with initially unresectable locally advanced disease Interval imaging of chest, abdomen and pelvis is recommended for systemic treatment response assessment, mostly with CT – although alternative imaging techniques may be used to monitor known disease sites (e.g. MRI for bone lesions) Platinum/fluoropyrimidine doublet alone or in combination with further compounds (triplet combinations; with epirubicin or with taxanes) are recommended for fit patients with advanced gastric cancer [I, A] All combinations like the ECF, ECX, EOF and EOX regimens provide broadly similar efficacy Within doublet and triplet regimens, capecitabine improves OS compared with infused 5-FU [I, A] A 3-‍weekly DCF regimen improves OS, but increases toxicity, including febrile neutropaenia [I, C]; a substantially modified 2-‍weekly DCF regimen is tolerable and effective [II, B] The FLOT regimen is associated with encouraging survival results [II, B], but Phase III data are not available FOLFIRI may be considered as an alternative to platinum-‍based therapy for selected patients"
},
{
	"page":"ENAS5283_8.3.3.0",
	"text":"8.3.3.0 Elderly patients with gastric cancer There are few randomised data in elderly patients Phase II trials have shown comparable survival with capecitabine/‍oxaliplatin, FOLFOX, single-‍agent capecitabine and S-1 (in Asian patients) [III, B] Response rates or OS following chemotherapy are similar in patients ≥70 years and younger patients [II, B] The triple agent regimen FLOT shows a trend towards improved PFS, compared with FLO, but increased toxicity [II, B] Generally, chemotherapy treatment decisions should consider the functional age of the patient, including comorbidities and PS, and geriatric assessment may also be helpful"
},
{
	"page":"ENAS5283_8.3.4.0",
	"text":"Ramucirumab has shown improved OS in two phase III trials: Compared with placebo when administered as a single agent and when added to paclitaxel compared with paclitaxel alone [I, A] 8.3.4.0 Second-‍ and further-‍line treatment Chemotherapy with a taxane (docetaxel, paclitaxel), or irinotecan, or ramucirumab, either as single agent or in combination with paclitaxel, is recommended for PS 0–1 patients [I, A] Paclitaxel and irinotecan seem to have similar efficacy [I, A] In patients with disease progression >3 months following first-‍line chemotherapy, re-‍challenge with the same drug combination may be considered as an additional treatment option [IV, C] In patients with symptomatic, locally advanced or recurrent disease, hypofractionated RT is an effective and well-‍tolerated treatment modality that may palliate bleeding, obstructive symptoms or pain [III, B]"
},
{
	"page":"ENAS5283_8.4.0.0",
	"text":"8.4.0.0 Personalised med. & targeted Tx Trastuzumab in combination with capecitabine or 5-FU and cisplatin is recommended for the treatment of patients with HER2-‍positive advanced gastric cancer [I, A] Bevacizumab, anti-‍EGFR and anti-‍MET/HGF therapies do not provide (substantial) survival benefits Immunotherapies, such as pembrolizumab and nivolumab, may provide durable benefit for some patients with advanced gastric cancer"
},
{
	"page":"ENAS5283_8.5.0.0",
	"text":"8.5.0.0 Specific situations Metastasectomy Gastrectomy in patients with limited metastatic disease does not improve survival [I, A] Currently, gastrectomy and metastasectomy should be considered experimental for patients with gastric cancer Peritoneal metastases In patients with peritoneal metastases, the use of cytoreductive surgery plus HIPEC has been studied but this approach cannot yet be recommended outside the context of clinical research Signet cell tumours Standard chemotherapy or surgical approaches should not be used differently for these patients"
},
{
	"page":"ENAS5283_8.6.0.0",
	"text":"FOLLOW-UP, LONG-TERM IMPLICATIONS AND SURVIVORSHIP 8.6.0.0 F-up, long term implic. & survivorship Regular follow-‍up may allow investigation and treatment of symptoms, psychological support and early detection of recurrence, although there is no evidence that it improves survival outcomes [III, B] Follow-‍up should be tailored to the individual patient and the stage of the disease [V, B] Dietary support for vitamin and mineral deficiencies is recommended for patients on either a radical or a palliative pathway [V, B] In the advanced disease setting, identification of patients for second-‍line chemotherapy and clinical trials requires regular follow-‍up to detect symptoms of disease progression prior to significant clinical deterioration [IV, B] If relapse/disease progression is suspected, a clinical history, physical examination and directed blood tests should be carried out, with radiological investigations in patients who are candidates for further chemotherapy or RT [IV, B]"
},
{
	"page":"ENAS5283_9.0.0.0",
	"text":"8.0.0.0 Glossary 5-FU 5-‍fluorouracil AC adenocarcinoma AEG adenocarcinoma of the oesophago-‍gastric junction AFP alpha foetoprotein AJCC American Joint Committee on Cancer AUC area under the curve BCLC Barcelona Clinic Liver Cancer BSC best supportive care BTC biliary tract cancer CA carbohydrate antigen CCA cholangiocarcinoma CEUS contrast-‍enhanced ultrasound CF cisplatin/‍fluorouracil CHA common hepatic artery ChT chemotherapy CIN chromosomal instability CP Child-‍Pugh CPGs Clinical Practice Guidelines CRT chemoradiotherapy CT computed tomography cTNM clinical tumour node metastasis CX cisplatin/‍capecitabine D1 dissection removal of perigastric lymph nodes D2 dissection removal of perigastric lymph nodes plus those along the left gastric, common hepatic and splenic arteries and coeliac axis dCCA distal cholangiocarcinoma DCF docetaxel/‍cisplatin/‍5-‍fluorouracil DEB-‍TACE drug-‍eluting beads transarterial chemoembolisation ECF epirubicin/‍cisplatin/‍5-‍fluorouracil ECOG Eastern Cooperative Oncology Group ECX epirubicin/cisplatin/‍capecitabine EGFR epidermal growth factor receptor EHS extrahepatic spread EMR endoscopic mucosal resection ENT ear, nose and throat EOF epirubicin/‍oxaliplatin/‍5-‍fluorouracil EOX epirubicin/‍oxaliplatin/‍capecitabine ERCP endoscopic retrograde cholangiopancreatography ESD endoscopic submucosal dissection ESGE European Society of Gastrointestinal Endoscopy ESMO European Society for Medical Oncology ESPEN European Society for Clinical Nutrition and Metabolism EUS endoscopic ultrasound FA folinic acid FDG-‍PET 18F-‍fluorodeoxyglucose positron emission tomography FGFR2 fibroblast growth factor receptor 2 FLO 5-‍fluorouracil/leucovorin/oxaliplatin FLOT 5-‍fluorouracil/‍leucovorin/‍oxaliplatin/‍docetaxel FNA fine needle aspiration FOLFIRI infusional 5-‍fluorouracil/‍leucovorin/‍irinotecan FOLFIRINOX folinic acid/‍5-‍fluorouracil/‍irinotecan/‍oxaliplatin FOLFOX 5-‍fluorouracil/leucovorin//oxaliplatin GBC gallbladder cancer GEJ gastroesophageal junction GI gastrointestinal GIST gastrointestinal stromal tumours GOR grade of recommendation HCC hepatocellular carcinoma HDGC hereditary diffuse gastric cancer HER2 human epidermal growth factor receptor 2 HGF hepatocyte growth factor HIPEC hyperthermic intraperitoneal chemotherapy iCCA intrahepatic cholangiocarcinoma IHC immunohistochemistry ISH in situ hybridisation L lymph vessel infiltration LDH lactate dehydrogenase LFT liver function test LOE level of evidence LV leucovorin m mucosal infiltration MDT multidisciplinary team MRCP magnetic resonance cholangiopancreatography mRECIST modified Response Evaluation Criteria in Solid Tumors MRI magnetic resonance imaging MS-CT multislice-‍computed tomography MSI microsatellite instability MVI macroscopic vascular invasion N node OGJ oesophago-‍gastric junction OLT orthotopic liver transplant OS overall survival pCCA perihilar cholangiocarcinoma pCR pathological complete remission PD-1 programmed death 1 PDP partial duodeno-‍pancreatectomy PEI percutaneous ethanol injection PET positron emission tomography PS performance status PSC primary sclerosing cholangitis PTC percutaneous trans-‍hepatic cholangiography pTNM pathological tumour node metastasis PV portal vein QoL quality of life R0 resection with negative margins R1 resection with microscopic residual disease RECIST Response Evaluation Criteria In Solid Tumours RFA radiofrequency ablation RT radiotherapy SCC squamous cell carcinoma sm submucosal infiltration SMA superior mesenteric artery SMV superior mesenteric vein SOAR Surgical Outcomes Analysis and Research T tumour TACE transarterial chemoembolisation TKI tyrosine kinase inhibitor TNM tumour node metastasis UICC Union for International Cancer Control ULN upper limit of normal US ultrasound V venous infiltration VEGF vascular endothelial growth factor WHO World Health Organization"
}
]